Genolution Develops Nucleic Acid Extraction Kit for Monkeypox Testing

Expected Increase in Sales through Expansion of Extraction Field
Contribution to Quarantine Efforts for Infectious Disease Prevention

[Asia Economy Reporter Hyungsoo Park] Genolution, a company specializing in in vitro diagnostic devices, announced on the 14th that it has enhanced its competitiveness in the extraction field by completing the development of a nucleic acid extraction kit for monkeypox testing.

Genolution conducted efficiency evaluations using the developed monkeypox nucleic acid extraction kit, NX Viral DNA Kit, through its distributor in the United Arab Emirates, including samples from monkeypox patients (plasma, serum, nasopharyngeal swabs). The company introduced that the test results for both positive and negative samples were normally derived through this kit, successfully developing a nucleic acid extraction kit to determine monkeypox virus infection.

The monkeypox nucleic acid extraction kit developed by Genolution is a nucleic acid extraction kit used for PCR testing to confirm monkeypox virus infection by using viral nucleic acid (Viral DNA) extracted from human samples. It can be tested through Genolution’s nucleic acid extraction equipment, which has been sold to over 50 countries worldwide, including South Korea. The company expects an increase in sales demand not only domestically but also in overseas markets.

A company official said, "As the number of COVID-19 confirmed cases increases recently, concerns about the spread of monkeypox are growing in Europe and the United States," adding, "The monkeypox PCR nucleic acid extraction kit developed by Genolution can contribute to quarantine efforts to block infectious diseases." He continued, "Genolution’s products will be sold in various infectious disease markets," and "this will be a good opportunity leading to performance."

Genolution recently launched the NX-DUO product, which enables large-volume nucleic acid extraction and liquid biopsy simultaneously. The company has officially started targeting the liquid biopsy market.